Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Diffuse Large B-Cell Lymphoma in Young Adults

April 12, 2016

Join Ahmet Dogan, MD, PhD and Andrew Zelenetz, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to diffuse large B-cell lymphoma (DLBCL) in Young Adults.

Diffuse large B‑cell lymphoma is the most common histologic subtype of non‑Hodgkin’s lymphoma (NHL) diagnosed in young adults (20-29 years).  Gene expression profiling (GEP) studies have shown that DLBCL is a heterogeneous group of distinct molecular subtypes with varied natural history and response to therapy. Germinal center B-cell (GCB) subtype and primary mediastinal B-cell lymphoma (PMBL) are the 2 molecular subtypes of DLBCL that are predominantly diagnosed in young adults. PMBL is more often diagnosed in young women. CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like chemotherapy regimens have been shown to be effective first-line treatment options for low-risk DLBCL in young adults. However, the optimal treatment of DLBCL in young adults remains unclear and the prognosis of DLBCL in this population continues to be inferior to that in children.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the molecular heterogeneity of DLBCL and its implications in the management of DLBCL in young adults
  • Identify the rationale for the development of novel therapeutic strategies and the mechanism of action of novel targeted therapies
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
04/11/2016
Course expires: 
06/08/2016
Event starts: 
04/12/2016 - 2:15pm
Event ends: 
04/12/2016 - 3:15pm
Cost:
$0.00

Ahmet Dogan, MD, PhD
Memorial Sloan Kettering Cancer Center

Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-016-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Accreditation Period

Course opens: 
04/11/2016
Course expires: 
06/08/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing